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Mutant TDP-43 in motor neurons promotes
the onset and progression of ALS in rats
Cao Huang,1 Jianbin Tong,1 Fangfang Bi,1 Hongxia Zhou,1,2 and Xu-Gang Xia1
1Department

of Pathology, Anatomy and Cell Biology, and 2Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Amyotrophic lateral sclerosis (ALS) is characterized by progressive motor neuron degeneration, which ultimately leads to paralysis and death. Mutation of TAR DNA binding protein 43 (TDP-43) has been linked to the
development of an inherited form of ALS. Existing TDP-43 transgenic animals develop a limited loss of motor
neurons and therefore do not faithfully reproduce the core phenotype of ALS. Here, we report the creation of
multiple lines of transgenic rats in which expression of ALS-associated mutant human TDP-43 is restricted to
either motor neurons or other types of neurons and skeletal muscle and can be switched on and off. All of these
rats developed progressive paralysis reminiscent of ALS when the transgene was switched on. Rats expressing
mutant TDP-43 in motor neurons alone lost more spinal motor neurons than rats expressing the disease gene
in varying neurons and muscle cells, although these rats all developed remarkable denervation atrophy of
skeletal muscles. Intriguingly, progression of the disease was halted after transgene expression was switched
off; in rats with limited loss of motor neurons, we observed a dramatic recovery of motor function, but in rats
with profound loss of motor neurons, we only observed a moderate recovery of motor function. Our finding
suggests that mutant TDP-43 in motor neurons is sufficient to promote the onset and progression of ALS and
that motor neuron degeneration is partially reversible, at least in mutant TDP-43 transgenic rats.
Introduction
Amyotrophic lateral sclerosis (ALS) is characterized by progressive
degeneration of motor neurons and denervation atrophy of skeletal muscles. The disease inexorably progresses to paralysis and to
death, often within 5 years after diagnosis. While ubiquitinated
TAR DNA binding protein 43 (TDP-43) inclusion is a characteristic of sporadic ALS, pathogenic mutation of TDP-43 causes an
inherited form of ALS (1, 2). Forced expression of either WT or
mutant TDP-43 in mice and rats causes compound phenotypes,
including cortical dementia and paralysis (3–9). Cortical pathology
in transgenic animals is expected, as TDP-43 proteinopathy is identified in sporadic frontotemporal lobe dementia (FTLD) (2, 10).
TDP-43 is highly conserved and is tightly regulated (7, 11). Overexpression of human TDP-43 in mice deregulates the mouse TDP-43,
and this interference may be pathogenic (7). However, forced
expression of WT mouse TDP-43 causes similar pathology in mice
(9), suggesting that increased expression of normal TDP-43 is neurotoxic. As a ribonucleoprotein (12), TDP-43 binds to both DNA
and RNA sequences of multiple genes (13, 14). Alteration in TDP43 expression interrupts mRNA processing of a number of genes
(15, 16). While the nature of TDP-43 mutation remains unclear,
mutation or deregulation of TDP-43 may affect multiple cellular
functions. Animal models that have been reported overexpress
TDP-43 restrictedly in the forebrain or globally in all the tissues
and thus develop limited or no loss of motor neurons (3–9), insufficiently reproducing the core phenotype of ALS.
ALS is currently incurable because the most effective drug, riluzole, only extends a patient’s life by several months. In the SOD1
transgenic model of ALS, β-lactam antibiotics stimulate the
expression of the glutamine transporter and produce a therapeutic effect (17). Knocking down the expression of mutant SOD1
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by RNAi produces a therapeutic effect, but does not prevent
the disease from progression in transgenic mice (18–20). In the
development of effective therapies for ALS, a compelling need is
to determine whether ALS could be prevented from progression
at certain disease stages. Motor neurons may undergo retrograde
degeneration in ALS, and the motor axon terminals are considered
the primary targets of degeneration in ALS (3, 21). It is not known
whether a functional recovery could be obtained at early disease
stages and how functional recovery is related to the integrity of
motor circuitry in ALS.
To induce neurodegenerative diseases, disease factors may not be
required to be present in all neurons and glia, although unhealthy
cells may interact aberrantly with neighboring cells to initiate or
to propagate neurodegeneration. Overexpression of mutant huntingtin in multiple types of neurons, but not in cortical pyramidal neurons alone, causes cortical neuropathology in mice (22).
Neurons of the same type may degenerate in distinctive ways in
response to mutation of different genes. Purkinje neurons degenerate cell autonomously in response to mutation of the npc1 gene
(23), but they degenerate non–cell autonomously in response to
mutation of the ataxia-7 gene (24). In mice, restricted overexpression of mutant SOD1 in motor neurons does not cause neuron
death (25), although mutant SOD1 in neurons is a primary determinant of disease onset (26). While forced expression of normal
SOD1 in mice fails to induce ALS phenotypes (27), overexpression
of normal TDP-43 causes profound neurodegeneration (7, 9). In
addition, TDP-43 proteinopathy is not observed in ALS caused
by mutation in sod1 (28). Mutant SOD1 and TDP-43 may cause
one disease by varied mechanisms. How motor neurons degenerate (cell autonomously or non–cell autonomously) in response to
TDP-43 mutation remains to be determined.
Using a Tet-regulatory system, we created multiple lines of
transgenic rats expressing mutant human TDP-43 reversibly and
restrictedly in motor neurons or in varying types of neurons and
skeletal muscles. Overexpression of mutant TDP-43 in neurons
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Figure 1
Restricted overexpression of mutant
human TDP-43 (hTDP-43) in neurons
is achieved in rats. (A) Immunoblotting
showed that the hTDP-43 transgene was
expressed in the spinal cord (SP) and
hippocampus (HP) of NEF-tTA/TRE–
TDP-43 M337V double-transgenic rats
soon after Dox was withdrawn (Dox–).
The rats were deprived of Dox at the age
of 60 days. Equal loading was confirmed
by probing the same membrane with an
antibody to GAPDH. (B–J) Human TDP43 immunoreactivity was examined in
the spinal cord (B–D), cortex (E–H), and
hippocampus (I and J) of NEF-tTA/TRE–
TDP-43M337V double-transgenic (C, D,
and G–J) and NEF-tTA single-transgenic (B, E, and F) rats. Coronal sections
of neocortex were counterstained lightly
with hematoxylin to display the nuclei
(E–H). (K–P) Double-label fluorescence
staining revealed that human TDP-43
(green, K, M, N, and P) was colocalized
with the neuronal marker NeuN (red,
L and M), but was not colocalized with
the astrocyte marker GFAP (red: O and
P) in the cortex. Rats were examined
10 days after Dox withdrawal. Scale
bars: 200 μm (B, C, and I); 100 μm (E
and G); 20 μm (D, F, H, and J–P).

and in muscles caused progressive paralysis in rats, with moderate
loss of spinal motor neurons, whereas restricted overexpression
of mutant TDP-43 in motor neurons alone caused progressive
paralysis in rats, with profound loss of spinal motor neurons. We
treated paralyzed rats with doxycycline (Dox) to suppress further
expression of the mutant TDP-43 after disease onset and observed
a recovery of motor function in the transgenic rats. Functional
recovery was moderate in the rats with profound loss of motor
neurons, but it was dramatic in paralyzed rats with limited loss of
motor neurons. Our findings suggest that motor neuron degeneration can be stopped from progression and that functional recovery is correlated with the integrity of motor neurons.
Results
Overexpression of mutant TDP-43 in neurons and muscles causes progressive paralysis in rats. We previously showed that ubiquitous overexpression of mutant TDP-43 in rats causes early onset and rapid
progression of paralysis reminiscent of ALS (3). To improve the
rat model, we intended to overexpress mutant TDP-43 selectively
in neurons and chose the regulatory elements (promoter) of the
human neurofilament heavy chain (NEF) gene to direct transgene
expression (Supplemental Figure 1; supplemental material available
online with this article; doi:10.1172/JCI59130DS1). In our TDP-43
transgenic rats (3, 29), tetracycline response element (TRE) drives
TDP-43 transgene, whose expression fully depends on the activity
of tetracycline-controlled transactivator (tTA). A short fragment
(8.5 kb) of human NEF promoter synthesizes transgene in differentiated neurons in mice (30). We used a long fragment (18 kb) of


the NEF promoter to drive tTA transgene in rats. We established
a single-copy transgenic line that exhibits X chromosome–linked
transmission of the NEF-tTA transgene (Supplemental Figure 1).
To avoid gene insertion–caused mutation, we only used female
rats heterozygous for NEF-tTA in the following studies. By crossing NEF-tTA transgene onto a TRE–TDP-43M337V transgenic background (line 16), we detected a substantial Dox-regulated expression of human TDP-43 transgene (Figure 1, A–J). Expression of the
transgene was restricted in neurons (Figure 1, K–M) and was not
detected in astrocytes (Figure 1, N–P) — the largest population of
nonneuronal cells in the CNS. Unexpectedly, skeletal muscles also
expressed human TDP-43 transgene (Supplemental Figure 1).
To induce disease phenotypes in adult rats, we deprived NEF-tTA/
TRE–TDP-43M337V double-transgenic rats of Dox at the age of 60 days
and observed a full activation of mutant TDP-43 gene in rats by the
age of 70 days (Figure 1A). Two weeks after mutant TDP-43 was
expressed, the mutant rats began losing grip strength and mobility
(Figure 2, A and B), displaying the early signs of paralysis (disease
onset). Within 3 weeks after mutant TDP-43 activation, rats lost
the ability to retract hind legs (Figure 2, A–C, and Supplemental
Video 1). To accurately assess motor neuron death in rats, we used
unbiased stereological cell counting. In our publications (3, 31),
we counted the number of motor neurons in 1 spinal segment
(L3). To increase the accuracy of cell counting, here we counted
the number of motor neurons in a long segment of lumbar cords
(L3–L5). Stereological cell counting revealed a moderate, but significant, loss of neurons in the spinal cord and dentate gyrus of
transgenic rats at disease end stages (Figure 2, D–K). In mutant
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Figure 2
Overexpression of mutant TDP-43 in neurons causes progressive paralysis in rats. (A) The grip strength of forepaws (f) and hind paws (h) was
measured for NEF-tTA/TRE–TDP-43M337V double-transgenic (M337V) and NEF-tTA single-transgenic rats. Data are means ± SD (n = 7). (B)
Open-field assay revealed an unrecoverable reduction of mobility in M337V rats after TDP-43 transgene was turned on. Data are means ± SD
(n = 7). (C) M337V rats rapidly developed paralysis after the transgene was turned on. Within 2 to 3 days, disease progressed from paralysis
stage to end stages. (D–I) Cresyl violet staining revealed the structure of frontal cortex (D and E), hippocampus (F and G), and the ventral horn
of the lumbar spinal cord (H and I). The tissues were taken from M337V rats at disease end stages (E, G, and I) or from NEF-tTA rats at matched
ages (D, F, and H). (J and K) Stereological cell counting revealed the number of motor neurons (>25 μm in diameter) in lumbar cords (L3–L5)
and revealed the number of neurons in dentate gyrus. Data are means ± SD (n = 5). *P < 0.05. All rats used were females and were constantly
given Dox in drinking water (50 μg/ml) until they were 60 days old. Scale bars: 100 μm (D–E, H, and I); 200 μm (F and G).

TDP-43 transgenic rats at paralysis stages, toluidine blue staining
and electromicroscopy revealed degenerating axons in the ventral,
but not in the dorsal, roots (Figure 3, K–N, and Supplemental Figure 2, C and D). Silver staining revealed degenerating neurons in
the ventral horn of the lumbar cord (Supplemental Figure 2, A and
B). At paralysis stages, mutant TDP-43 transgenic rats displayed
grouped atrophy of skeletal muscles revealed by H&E staining
(Figure 3B) and by histochemistry for nonspecific esterase (Figure
3E) and ATPase (Figure 3H). In contrast, NEF-tTA single-transgenic rats did not display any of these pathological changes (Figures 2 and 3; Supplemental Figure 2). Restricted overexpression of
mutant TDP-43 in neurons and in muscles induced motor neuron
degeneration and denervation atrophy of muscles, reproducing
the key features of ALS in rats.
Ubiquitinated TDP-43 inclusion is a characteristic of sporadic
ALS and FTLD (2). We next examined TDP-43 inclusion, but did
not observe typical TDP-43 inclusion in mutant TDP-43 transgenic rats at paralysis stages (Figure 1, D and H). We detected rare
ubiquitin aggregates in the cortex (Supplemental Figure 3), but
not in the spinal cord (data not shown), of paralyzed rats. Our
finding confirmed that TDP-43 inclusion is not essential to neuron death, at least in rodent models (3, 7).
Removal of mutant TDP-43 partly restores motor function in ALS rats
expressing the disease gene in neurons and muscles. Restricted expression
of mutant TDP-43 in neurons and in muscles caused severe damage

to motor axons and to skeletal muscles (Figure 3 and Supplemental
Figure 2), but only caused a moderate loss of motor neurons in the
spinal cord (Figure 2). We determined the potential of functional
recovery in the diseased rats. Since expression of mutant TDP-43
in rats was subject to Dox regulation (Supplemental Figure 1), we
treated the rats with Dox to prevent the mutant TDP-43 transgene
from further expression after the rats developed paralysis (Figure 4).
To repress disease gene expression quickly, Dox was subcutaneously
injected and was simultaneously given in drinking water (Figure 4A).
Paralyzed rats were provided Dox-soaked soft food on the cage floor.
By the fifth day of Dox treatment, mutant TDP-43 was efficiently
suppressed (Figure 4A). Suppressing the mutant TDP-43 gene led
to restoration of motor function in rats (Figure 4, B–D, and Supplemental Videos 1–4). Dox-treated transgenic rats began to retract
hind legs by the seventh day and to totter around the cage by the
ninth day of Dox treatment. Open-field assay revealed a gradual
recovery of motor function in the Dox-treated rats (Figure 4E). Even
2 months after Dox treatment, grip strength recovered partially
(Figure 4F). Functional recovery was dramatic but incomplete in the
rats expressing mutant TDP-43 in neurons and in skeletal muscles.
Remodeling of motor units contributes to the functional recovery in Doxtreated transgenic rats. We examined the anatomical basis of functional recovery in Dox-treated transgenic rats. As expected, stereological
cell counting revealed no difference in the number of motor neurons between Dox-treated and Dox-untreated ALS rats (Figure 3R).
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Figure 3
Motor units are remodeled in diseased rats after mutant TDP-43 is removed. (A–C) H&E staining of gastrocnemius muscle revealed normal
structure in NEF-tTA transgenic rats (A), grouped atrophy (arrows) in NEF-tTA/TRE–TDP-43M337V double-transgenic rats at disease end stages
(B, M337V), and regenerated muscle cells of varied sizes in diseased M337V rats after Dox treatment (C, M337V + Dox). (D–F) Histochemistry
for nonspecific esterase revealed accumulated muscle fibers of varied sizes, but with similar staining (arrowheads), in M337V rats after Dox treatment. (G–I) Staining for ATPase (pH 4.6) revealed regenerated muscle cells of varied sizes in M337V rats after Dox treatment (I). (J–O) Toluidine
blue staining revealed the structure of L3 ventral (J–L) and dorsal (M–O) roots. Scale bars: 30 μm. (P) Myofibers with or without centered nucleus
were quantified on the cross sections of gastrocnemius stained with H&E. (Q) The cross areas of myofibers were quantified with ImageJ on the
cross sections of gastrocnemius stained for ATPase. Quantification was done on 3 photos of the cross section of gastrocnemius, and each group
contained 4 rats (P and Q). Data are means ± SD (n = 4). (R) Unbiased cell counting revealed the number of motor neurons (>25 μm) in the
lumbar cords (L3–L5). Data are means ± SD (n = 7). *P < 0.05. All rats were deprived of Dox to induce disease at 60 days of age. Dox-untreated
rats were examined at disease end stages, and Dox-treated rats were examined 2 months after Dox treatment (Q and R).

Morphological analyses showed that degenerating motor axons
were eliminated in Dox-treated ALS rats (Figure 3, J–Q). H&E staining revealed that damaged muscle fibers in the gastrocnemius muscle were cleared and that muscle fibers of varied sizes were regenerated (Figure 3, A–C). Regenerating myofibers displayed centered
nuclei and increased in size (Figure 3, P and Q).
While the histochemistry for nonspecific esterase and ATPase
revealed normal myofibers with uniform sizes, polygonal shapes,
and eccentric nuclei (Figure 3, D and G), these stainings revealed
denervated myofibers with small sizes and angulated shapes
(Figure 3, E and H). Nonspecific esterase staining displayed normal
myofibers with pale yellow to brown color (Figure 3D), but displayed denervated or newly regenerated myofibers with red-brown
color (Figure 3, E and F). ATPase staining (pH 4.6) can distinguish
3 types of myofibers, with light to dark colors. ATPase staining
revealed a mosaic distribution of different myofibers in normal
muscles (Figure 3G), but it revealed the grouping of myofibers of the
same types in denervated or newly regenerated muscles (Figure 3,
H and I). Histological analyses suggested that motor units were
remodeled in Dox-treated transgenic rats.


Novel tTA transgenic rats are created to express transgenes restrictedly in motor neurons. To determine whether motor neuron death
is a cell-autonomous process in TDP-43–related ALS, we developed multiple transgenic rat lines that express tTA transgene
restrictedly in motor neurons (Figure 5, Supplemental Figures 4 and 5). Previous studies showed that the promoter of
the choline acetyltransferase (ChAT) gene directs synthesis of
transgenes selectively in spinal motor neurons in mice (32). We
isolated mouse ChAT promoter from a BAC clone and used it to
drive tTA transgene in rats. We obtained 3 expression lines that
carry 2, 5, or 9 copies of the tTA gene (Supplemental Figure 4).
Individual lines were designated as ChAT–tTA-2, -5, or -9. It is
a technical challenge to measure the expression levels of transgene in a single cell population in animals. Thus, we crossed
each ChAT-tTA transgenic line with TRE–TDP-43M337V (line 16)
rats and purified motor neurons from the double-transgenic
embryos (embryonic day 14) using immunopanning (33). We
then determined the expression levels of the TDP-43M337V transgene in purified motor neurons and detected varying expression
of human TDP-43 in individual ChAT-tTA lines (Supplemen-
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Figure 4
Suppressing mutant TDP-43 expression results in partial recovery of motor function in rats. (A) Immunoblotting revealed that Dox treatment (Dox+) suppressed
the expression of mutant TDP-43 transgene (hTDP-43)
as early as 5 days after Dox was administered. Equal
loading was probed with an antibody to GAPDH. Tissues: FB, forebrain; SM, skeletal muscle. (B–D) Representative photographs show a M337V rat at paralysis
stage (B) and at 10 days (C) and 2 months (D) after
Dox treatment. (E) Open-field assay revealed a quick
recovery of mobility in M337V rats after the transgene
was turned off by Dox treatment (Dox+). (F) The grip
strength of hind paws was partially recovered in M337V
rats after the transgene was turned off. NEF-tTA denotes
NEF-tTA single-transgenic rats, and M337V denotes
NEF-tTA/TRE–TDP-43M337V double-transgenic rats. Data
are means ± SD (n = 7).

tal Figure 4, E–J). Compared with the NEF-tTA line, ChAT-tTA
lines 5 and 9, but not 2, expressed the transgene at higher levels
(Supplemental Figure 4, G, I, and J).
To facilitate determination of the transgene expression profile,
we created a tTA reporter line that carries the LacZ transgene
under control of the TRE promoter (Supplemental Figure 5A).
We established a 3-copy TRE-LacZ line and crossed it with a
ChAT–tTA-9 line to determine tTA expression profile (Figure 5,
A–C, and Supplemental Figure 5, B–E). In ChAT–tTA-9/TRE-LacZ
double-transgenic rats, expression of the LacZ gene was restricted
to the ventral horn of the spinal cord (Figure 5, B and C). Doublelabel immunostaining revealed that LacZ immunoreactivity was
restricted in ChAT-positive cells and that more than 60% of motor
neurons expressed LacZ in the ChAT–tTA-9 line (Supplemental
Figure 5, B–E). In contrast, about 40% of motor neurons expressed
LacZ in the ChAT–tTA-2 and -5 lines. We then focused our studies
on the ChAT–tTA-9 line.
Motor neurons undergo cell-autonomous death in TDP-43 transgenic
rats. We crossed ChAT-tTA lines (ChAT–tTA-5 and ChAT–tTA9) with TDP-43M337V transgenic rats (line 16) to examine disease
induction, and we focused our studies on the ChAT–tTA-9 line, as
this line expresses transgenes in the most motor neurons (Supplemental Figure 5). Similar to the reporter gene LacZ (Figure 5, B
and C, and Supplemental Figure 5), mutant human TDP-43 was
expressed restrictedly in the ventral horn of the spinal cord in
ChAT–tTA-9/TDP-43M337V rats (Figure 5, D and E). Double-label
immunostaining revealed that human TDP-43 was colocalized
with the motor neuron marker ChAT (Figure 5, J–L), but was not
colocalized with the oligodendrocyte marker APC (Figure 5F) or
the astrocyte marker GFAP (Figure 5, G–I). The results suggest that
expression of TDP-43M337V is restricted in spinal motor neurons.
To induce disease phenotypes in adult rats, we gave transgenic
rats Dox in drinking water until the rats were 60 days old (Figure 6A
and Supplemental Figure 6A). Sprague Dawley rats are sexually

mature at the age of 70 days. In ChAT–tTA-9/TDP-43M337V transgenic rats, human TDP-43 was undetectable in the presence of Dox,
but was detected by 3 days off Dox (Figure 6B). Human TDP-43
was not detectable in the skeletal muscles (Figure 6B). Soon after
expression of mutant TDP-43, rats began losing grip strength and
motor activity, as revealed by open-field assay and grip-strength
measure (Figure 6, C and D). By the age of 70 days (10 days off
Dox), most mutant rats developed the early signs of paralysis
(Figure 6E). Rats reached disease end stages within a week after
disease onset (Figure 6F). On average, the duration of disease progression was less than 2 weeks (Figure 6, E and F). Unbiased stereological counting revealed that more than 60% of spinal motor
neurons were lost in mutant TDP-43 transgenic rats at disease end
stages (Figure 6, G–K). Interestingly, the size of surviving motor
neurons and the volume of ventral lumbar cords were unaltered
at disease end stages (Figure 6, L and M). Toluidine blue staining
revealed that axons in the ventral roots (motor axons), but not in
the dorsal roots (sensory axons), were damaged (Figure 7, N–S). As
a result of motor neuron death, groups of skeletal muscle fibers
were atrophied, as revealed by H&E staining (Figure 7, E and F)
and by histochemistry for nonspecific esterase (Figure 7, H and I)
and ATPase (Figure 7, K and L). Restricted overexpression of
mutant TDP-43 in motor neurons caused a severe loss of motor
neurons and motor axons and caused a denervation atrophy of
skeletal muscles in ChAT–tTA-9/TDP-43M337V transgenic rats.
We next characterized ChAT–tTA-5/TDP-43M337V transgenic rats
(Supplemental Figure 6). When Dox was withdrawn at the age of
60 days, rats displayed disease onset by the age of 85 days (Supplemental Figure 6, A and B), but did not reach disease end stages
by the age of 150 days. The ChAT–tTA-5 line directed transgene
expression in less than 50% of spinal motor neurons (Supplemental Figure 5E), and thus, ChAT–tTA-5/TDP-43M337V rats would not
lose enough motor neurons to cause full paralysis. Indeed, only
about 30% of motor neurons were lost in the rats by 150 days of
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minated at disease end stages (by
age of 80 days), and Dox-treated rats
were terminated at 90 days of age.
In Dox-treated transgenic rats, H&E
staining of gastrocnemius revealed
remodeled motor units: some muscle
fibers with centered nuclei, muscle
fibers of varied sizes, and absence of
atrophied muscle fibers (Figure 7,
E–G, and T). Histochemistry for nonspecific esterase (Figure 7, H–J) and
ATPase (Figure 7, K–M) showed that
muscle cells of the same types, but
with varied sizes, were grouped, suggesting a remodeling of motor units.
During functional recovery, muscle
fibers increased in size (Figure 7U).
Toluidine blue staining revealed that
most degenerated motor axons were
Figure 5
Restricted overexpression of mutant TDP-43 in motor neurons is achieved in transgenic rats. (A–C) cleared in the ventral roots (Figure
X-gal staining revealed that the positive cells were restricted to the ventral horns of the lumbar cord in 7, N–P). Interestingly, stereological
ChAT–tTA-9/TRE-LacZ double-transgenic (B and C), but not in TRE-LacZ single-transgenic (A), rats. cell counting revealed that the numCross sections of lumbar cords were first stained with X-gal and then were counterstained with fast ber of spinal motor neurons (L3–L5)
red. (D and E) Immunohistochemistry revealed that human TDP-43 immunoreactivity was restricted between Dox-treated and Doxin large cells in the ventral horns of the lumbar cord. ChAT–tTA-9/TRE–TDP-43M337V transgenic rat untreated transgenic rats was similar
at 70 days old was examined for human TDP-43 expression at 10 days after Dox withdrawal. (F–L)
(Figure 7V). These findings suggest
Double-label immunofluorescence staining revealed that human TDP-43 (red, F, G, I, J, and L) was
that
degenerating motor neurons
not colocalized with APC (a marker of oligodendrocytes; F, green) or GFAP (a marker of astrocytes;
H and I, green), but was colocalized with ChAT (a marker of motor neurons; K and L, green). Scale cannot be rescued and that survived
motor units can be remodeled.
bars: 100 μm (A, B, and D); 50 μm (C); 20 μm (E–L).
Distribution of reactive astrocytes and
microglia differs in the spinal cord of ALS rats.
age (Supplemental Figure 6C). Accordingly, fewer motor axons in Glial cells play an important role in motor neuron degenerathe ventral roots were lost in ChAT–tTA-5/TDP-43M337V rats com- tion (34–36). We examined glial reaction to motor neuron death
pared with ChAT–tTA-9/TDP-43M337V rats (Supplemental Figure 6, in ChAT–tTA-9/TDP-43 M337V transgenic rats. Astrocytes and
H and I, and Figure 7, N–P). Overexpression of mutant TDP-43 at microglia were activated in the spinal cords of paralyzed rats (Figa low level and in fewer motor neurons caused moderate paralysis ure 8). Mutant TDP-43 transgenic rats lost a large quantity of
phenotypes in rats (Supplemental Figure 6).
motor neurons at disease end stages (Figure 6G). In rats with active
Removal of mutant TDP-43 prevents disease from progression in disease, reactive astrocytes distributed across the whole spinal cord
rats expressing the disease gene restrictedly in motor neurons. Com- and were not restricted to the ventral horns, where motor neurons
pared with NEF-tTA/TDP-43M337V rats (Figure 2), ChAT–tTA-9/ expressing mutant TDP-43 were dying (Figure 8, B, E, and N), but
TDP-43M337V rats displayed a more severe loss of motor neurons, but microglia were activated around diseased motor neurons in the
displayed a similar progression of paralysis phenotype (Figure 6). ventral horns (Figures 8, H and K). NG2-positive glia were also
We determined whether disease progression could be halted activated around diseased motor neurons (Figure 8, P–R). When
by stopping mutant TDP-43 expression after disease onset in disease progression was halted by Dox treatment (Figure 7, A–D),
ChAT–tTA-9/TDP-43M337V rats. When Dox was withdrawn from microglial reaction was quenched (Figure 8, I and L) and reactive
ChAT–tTA-9/TDP-43M337V rats at the age of 60 days (Figure 6A), astrocytes were restricted to the ventral horns where damaged
the rats developed an early paralysis phenotype by 70 days of age motor neurons resided (Figure 8, C, F, and O). Varied response of
and reached disease end stages by 78 days of age (Figure 6, C–F). glial cells may suggest a different role for astrocytes and microglia
Dox was thus withdrawn from rats that were 60 days old and was in the propagation and repair of neuronal damage in the disease.
added back 12 days later, so that mutant TDP-43 was expressed
Ubiquitin accumulates in motor neurons expressing mutant TDP-43 in
in the rats from 63 to 77 days of age (Figure 6B and Figure 7B). rats with paralysis. Similar to NEF-tTA/TDP-43M337V rats, ChAT–
We refer to restoring Dox as a treatment. Dox-untreated and tTA-9/TDP-43M337V rats did not develop TDP-43 inclusion in disDox-treated rats all developed paralysis at comparable speeds eased motor neurons (Supplemental Figure 7). As the disease probefore Dox produced an effect on disease gene expression gressed, mutant TDP-43 accumulated in the cytoplasm of motor
(Figure 7C). Soft food was provided to rats with paralysis. While neurons in transgenic rats (Supplemental Figure 7). In NEF-tTA/
the disease rapidly progressed to end stages in Dox-untreated TDP-43M337V rats at disease end stages, rare ubiquitin aggregates
rats, the disease stopped progressing at paralysis stages in Dox- were formed only in cortical neurons (Supplemental Figure 3). In
treated rats (Figure 7, C and D). Within a few days, Dox-treated contrast, ubiquitin accumulated in diseased motor neurons in
rats began to gain body weight and to gain partial recovery of ChAT–tTA-9/TDP-43M337V rats (Figure 9 and Supplemental Figure
motor activity (Figure 7, C and D). Dox-untreated rats were ter- 8). Accumulated ubiquitin delineated the cell body and neurites
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Figure 6
Restricted overexpression of mutant TDP-43 in motor neurons results in progressive paralysis and substantial motor neuron death. (A) A diagram
shows the course of gene induction and disease progression. ChAT–tTA-9/TRE–TDP-43M337V double-transgenic (M337V) rats were deprived of
Dox (Dox–) at 60 days of age. (B) Immunoblotting revealed induction of mutant TDP-43 transgene (hTDP-43) after Dox withdrawal (Dox–). (C)
Open-field assay measured mobility within 20 minutes. ChAT-tTA denotes ChAT–tTA-9 (line 9) transgenic rats. (D) The grip strength of 2 hind
paws was measured daily. Data are means ± SD (C and D, n = 10). (E and F) Graphs show the probability of disease onset and rat mortality.
Rats were counted at death when they reached disease end stages. 10 rats of equal sex composition were assessed in E and F. (G) Stereological cell counting revealed a profound loss of motor neurons (>25 μm in diameter) in the L3–L5 cords of M337V rats at end stages as compared
with ChAT-tTA rats at matched ages. Data are means ± SD (n = 8). *P < 0.01. (H–K) Representative photos of low (H and J) and high (I and
K) magnification show the lumbar cord of a M337V rat at disease end stage (J and K) or a ChAT-tTA rat at matched age (H and I). Scale bars:
200 μm (H and J); 60 μm (I and K). (L and M) Graphs show the average size of motor neurons in L3–L5 cords and the total volume of the ventral
horns of L3–L5 cord. Data are means ± SD (n = 8).

of diseased motor neurons expressing mutant TDP-43 (Figure 9E
and Supplemental Figure 8, B and C). Motor neurons with ubiquitin aggregates were few at disease onset, but were remarkably
increased at paralysis stages (Supplemental Figure 8G). Accumulated ubiquitin was detectable only in rats with active disease
(Figure 9, B, E, and G–I), but not in rats with disease halted by Dox
treatment (Figure 9, C and F). The results suggest that accumulated ubiquitin may be cleared after the disease is halted and that
ubiquitin accumulation may be an accompanying event of motor
neuron death in the disease caused by TDP-43 mutation.
Discussion
TDP-43 proteinopathy is implicated in sporadic ALS and FTLD
(2, 10). Mutation of TDP-43 causes an inherited form of ALS (1,
37–39). Most TDP-43 transgenic animal models reported on

develop a profound loss of cortical neurons, but only a few lines
develop a limited loss of motor neurons at disease end stages
(3–9, 40). To induce motor neuron death, mutant TDP-43 may
not be required to present in all types of related cells. To address
these questions, we created transgenic rats expressing mutant
human TDP-43 in inducible, reversible, and cell-specific manners. Mutant TDP-43 in motor neurons alone was sufficient to
induce motor neuron degeneration. Even at paralysis stages,
stopping the disease gene from further expression prevented
paralysis from progression and resulted in dramatic recovery of
motor function in mutant TDP-43 transgenic rats.
NEF-tTA/TDP-43 M337V and ChAT-tTA/TDP-43 M337V transgenic rats developed a similar disease phenotype — progressive
paralysis — reminiscent of ALS that is characterized by progressive degeneration of motor neurons and denervation atrophy of
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Figure 7
Suppressing mutant TDP-43 expression prevents disease from progression in rats. (A) A diagram shows induction (Dox withdrawal) and suppression (Dox addition) of mutant TDP-43 (hTDP-43) transgene. (B) Immunoblotting revealed gene suppression after Dox addition (Dox+). (C)
Open-field assay measured mobility within 20 minutes. ChAT-tTA denotes ChAT–tTA-9 rats, and M337V denotes ChAT–tTA-9/TRE–TDP-43M337V
rats. (D) The body weight of an individual rat at 66 days of age was used as the base for calculating alteration in body weight. Data are means ± SD
(C and D, n = 8). (E–M) H&E staining (E–G) and histochemistry for nonspecific esterase (H–J) and ATPase (K–M) revealed grouped atrophy of
skeletal muscle in Dox-untreated (F, I, and L) and varied sizes of muscle fibers in Dox-treated (G, J, and M) rats. Arrowheads point to grouped
atrophy, and arrow points to a neuromuscular junction. (N–S) Toluidine blue staining showed L3 ventral (N–P) and dorsal (Q–S) roots. All scale
bars: 30 μm. (T) Myofibers were quantified on cross sections of gastrocnemius stained with H&E. (U) The cross areas of myofibers were quantified with ImageJ on cross sections of gastrocnemius stained for ATPase. Quantification was done on 3 photos of the cross sections (T and U).
Data are means ± SD (n = 4 rats). *P < 0.05. (V) The number of motor neurons (>25 μm) is not different between Dox-treated and -untreated
M337V rats. The group of Dox-untreated M337V rats is identical to the M337V group of Figure 6G. Dox-treated rats were terminated at 90 days
of age. Data are means ± SD (n = 8).

skeletal muscles. The disease progressed rapidly to end stages in
these rat models. At disease end stages, NEF-tTA/TDP-43M337V
transgenic rats suffered from severe damage to motor units that
included impaired motor axons and grouped atrophy of skeletal muscles, although a moderate loss of spinal motor neurons
was observed. In contrast, ChAT-tTA/TDP-43M337V rats suffered
a heavy loss of motor neurons at disease end stages. Motor
function depends on the integrity of motor circuitry, including
motor neurons, motor axons, neuromuscular junctions, and
skeletal muscles. Damage to any of these elements may promote


onset and progression of paralysis. Both NEF-tTA/TDP-43M337V
and ChAT-tTA/TDP-43M337V transgenic rats reproduced the core
phenotypes of ALS.
ChAT-tTA/TDP-43M337V rats expressed mutant TDP-43 restrictedly in spinal motor neurons and developed a severe degeneration of motor neurons. The results suggest that mutant TDP-43
in motor neurons alone is sufficient to kill the cells. In response
to TDP-43 mutation, motor neurons can undergo cell-autonomous death. Our findings in TDP-43 transgenic rats strikingly
contrasts with the findings in SOD1 transgenic mice that do
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Figure 8
Astrocytes and microglia react
to motor neuron death in rats.
(A–L) Immunohistochemistry
revealed marked activation of
astrocytes (GFAP) and microglia
(Iba1) in the spinal cords of mutant
TDP-43 transgenic rats. (M–R)
Immunofluorescence staining
showed the distribution of astrocytes (GFAP) and NG2 glia in
the ventral horns of lumbar cords.
ChAT–tTA-9/TRE–TDP-43 M337V
double-transgenic (M337V) rats
were deprived of Dox at 60 days
of age and were completely paralyzed (end stage) by 78 days of
age. ChAT–tTA-9 single-transgenic rats were terminated at
matched ages. Randomly chosen M337V rats were treated
with Dox (M337V + Dox) to prevent mutant TDP-43 from further
expression after disease onset.
Dox-treated rats were terminated
at 90 days of age. Scale bars:
200 μm (A–C and G–I); 100 μm
(D–F, J–L, and M–R).

not develop motor neuron degeneration when mutant SOD1 is
overexpressed restrictedly in motor neurons (25, 41), underscoring the difference in pathogenesis between TDP-43 and SOD1
mutations. Our findings do not necessarily exclude that cells
other than motor neurons play an important role in TDP-43
pathogenesis. In fact, the severity of disease is not correlated with
the expression levels of mutant TDP-43 in motor neurons in our
transgenic rats. While ChAT-tTA/TDP-43M337V rats express mutant
TDP-43 restrictedly in motor neurons, NEF-tTA/TDP-43M337V
rats express the gene in motor neurons and in other cells, including the other neurons and skeletal muscles. Compared with
ChAT–tTA-9/TDP-43 M337V rats, NEF-tTA/TDP-43 M337V rats
expressed less mutant TDP-43 protein in motor neurons and
developed paralysis at comparable speeds, implying that cells
other than motor neurons may also play an important role in
TDP-43 pathogenesis. It remains to be determined whether
restricted expression of mutant TDP-43 in the other cells, such as
astrocytes and glia, is sufficient to induce motor neuron degeneration. Mutant TDP-43 in motor neurons alone is sufficient to
promote onset and progression of neurodegeneration. Although
overexpression of a mutant form of TDP-43 in motor neurons is
toxic in rats, this may not be representative of the consequences of this mutation in patients as (a) it is not known whether
this mutation causes this extent of overexpression of TDP-43 in
patients, (b) the disease course is much more rapid in rats than
in patients, implying that the underlying mechanisms may be

different, and (c) patients do not express mutant TDP-43 specifically in motor neurons. Therefore, ultimately, direct relevance to
the disease in humans is not known and remains to be tested.
Our 2 individual ChAT-tTA lines expressed mutant TDP-43
restrictedly in motor neurons and at varying levels. ChAT–tTA-5/
TDP-43M337V and ChAT–tTA-9/TDP-43M337V transgenic rats developed paralysis at similar ages, but ChAT–tTA-5/TDP-43M337V rats
displayed a much slower progression of the disease because this
line expressed less mutant TDP-43 protein in fewer motor neurons. In ALS patients, motor symptoms often begin focally and
progress contiguously. Consistently with focal onset of motor
symptoms, loss of lower motor neurons first occurs in the corresponding region of brain stem or spinal cord and propagates to
the other regions (42, 43). At postmortem analysis, more than 60%
of total lower motor neurons are lost and the neuronal loss is more
severe in the region first affected (42, 43). Most ALS patients die
within 3 years, but some survive more than 10 years. Our 2 individual transgenic lines reproduce the variation of disease progression in ALS, albeit with a time frame of weeks rather than years.
Mutations of TDP-43 and SOD1 are all linked to familial ALS.
While WT SOD1 is an excellent control for mutation in the gene
in transgenic studies, WT TDP-43 may not be. While pathogenic
mutation of TDP-43 definitely causes an inherited form of ALS,
TDP-43 is found to be ubiquitinated, hyperphosphorylated, and
aggregated in sporadic ALS, implying that WT TDP-43 may play a
role in ALS pathogenesis. Overexpression of the mutant, but not
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similar ages. Dox was added back to NEF-tTA/TDP-43M337V
rats at paralysis stages and to ChAT–tTA-9/TDP-43M337V rats
at disease onset. Mutant TDP-43 expression was stopped at
5 days on Dox in NEF-tTA/TDP-43M337V rats and at 6 days
on Dox in ChAT–tTA-9/TDP-43M337V rats. By the time of
mutant TDP-43 suppression, NEF-tTA/TDP-43M337V and
ChAT–tTA-9/TDP-43M337V rats approached disease end stages. Soon after the effect of Dox, progression of ALS halted
in Dox-treated rats. Dox treatment resulted in a dramatic
recovery of motor function in NEF-tTA/TDP-43M337V rats,
but only resulted in a moderate recovery of motor function
in ChAT–tTA-9/TDP-43M337V rats. By the effectiveness of
Dox, NEF-tTA/TDP-43M337V rats lost about 20% of spinal
motor neurons and ChAT–tTA-9/TDP-43M337V rats lost more
than 60% of the neurons, although denervation atrophy of
skeletal muscles was remarkable in all these rats. The potential of functional recovery in TDP-43 transgenic rats largely
depends on the viability of motor neurons. Compared with
RNAi-mediated gene silencing (18–20), the Tet regulatory
system turns on and off regulated genes readily and efficiently and is convenient for determining the reversibility of
disease phenotypes in animal models (29). Our findings sugFigure 9
gest that motor neuron degeneration can be stopped and the
Ubiquitin accumulates in the motor neurons of ALS rats. (A–F) Immunostaining disease can be prevented from progression, provided that an
revealed a marked accumulation of ubiquitin in the motor neurons of mutant
effective treatment is developed.
TDP-43 transgenic rats. (G–I) Confocal microscopy revealed that ubiquitin
In addition, TDP-43 inclusion was not detected in NEF-tTA/
aggregates accumulated in the motor neurons expressing mutant human
M337V and ChAT-tTA/TDP-43M337V rats. Consistent
TDP-43
M337V
TDP-43 (hTDP-43). ChAT–tTA-9/TRE–TDP-43
double-transgenic
(M337V) rats were deprived of Dox at 60 days of age and were paralyzed at with previous findings in TDP-43 transgenic rats and mice
the age of 78 days. ChAT–tTA-9 single-transgenic (ChAT-tTA) rats were ter- (3, 7), TDP-43 inclusion is rare and is not essential to neuron
minated at matched ages. Some M337V rats were treated with Dox (M337V death. In the absence of TDP-43 inclusion, TDP-43 accumu+ Dox) to prevent mutant TDP-43 from further expression after disease onset. lated in the cytoplasm as disease progressed. Few neurons
Dox-treated rats were terminated at 90 days of age. Scale bars: 200 μm in the cortex of NEF-tTA/TDP-43M337V rats contained clear
(A–C); 50 μm (D–F); 10 μm (G–I).
ubiquitin aggregates. Diseased motor neurons were full of
accumulated ubiquitin in ChAT-tTA/TDP-43M337V rats as
disease progressed. Intriguingly, ubiquitin aggregates were
the normal, SOD1 causes ALS phenotypes in rodents (27, 44, 45). not detectable after the disease stopped progressing. Gliosis was
In striking contrast, overexpression of both the mutant and the remarkable and was related to active motor neuron degeneration
normal TDP-43 causes neurodegeneration and disease phenotypes in TDP-43 transgenic rats. Although how motor neurons die in
in rodents, although mutant TDP-43 appears to be more toxic ALS remains to be determined, ubiquitin aggregation, gliosis,
than the WT form (3, 7). Previous findings suggest that elevated and cytoplasmic accumulation of TDP-43 are correlated to motor
levels of normal protein TDP-43 are sufficient to cause the disease. neuron death in mutant TDP-43 transgenic rats. In summary, we
Indeed, a genetic variant in the 3′ UTR region of TDP-43 causes a observed that motor neuron degeneration is partially reversible, at
significant increase in TDP-43 expression, and this TDP-43 variant least in TDP-43 transgenic rats.
has been associated with ALS and FTLD in 2 unrelated families
(46). Further, pathogenic mutation in TDP-43 elongates the life- Methods
time of TDP-43 protein and thus possibly increases the levels of Generation of transgenic rats. Transgenic rats were created on a sole Sprague
TDP-43 protein (47). While the functional effect of the TDP-43 Dawley background as described previously (29). The promoters of the
mutation on the protein remains to be determined, pathogenic human NEF gene and the mouse ChAT gene were isolated from BAC clones
mutation and elevated expression of TDP-43 prove neurotoxic. (CHORI: RP11-91J21 and RP24-256F2). Selected NEF and ChAT promotHere, we used mutant TDP-43 transgenic rats as one model for ers drove the tTA gene. The resulting constructs NEF-tTA and ChAT-tTA
testing the reversibility of motor neuron degeneration.
were linearized and injected into the pronuclei of rat single-cell embryos to
Disease progression in both NEF-tTA/TDP-43M337V and ChAT– produce transgenic founders. Transgenic rats were identified by PCR analtTA-9/TDP-43M337V rats was halted after expression of mutant ysis of rat tail DNA with the following primers: NEF-tTA, 5′-TCCACTTTTDP-43 was suppressed by Dox. Rats of these 2 lines began GAGGGGTCTCTG-3′ (forward) and 5′-AGCATCTCATCACTTCCCTG-3′
expressing mutant TDP-43 by 5 days off Dox. The speed of dis- (reverse); and ChAT-tTA, 5′-TCCAAGGCAGAGTTGATGAC-3′ (forward)
ease progression and the duration of disease were comparable and 5′-TGAGTTCCAGGCAAACCAAG-3′ (reverse). LacZ transgene was
between NEF-tTA/TDP-43M337V and ChAT–tTA-9/TDP-43M337V assembled downstream of the TRE promoter, and TRE-LacZ transgenic
rats. Mutant TDP-43 transgene was turned on in NEF-tTA/ rats were created (29). TRE-LacZ transgenic rats were identified by PCR
TDP-43M337V and ChAT–tTA-9/TDP-43M337V rats at the age of analysis with the following primers: 5′-TGACCTCCATAGAAGACACC-3′
60 days, so that rats of these 2 lines reached disease end stages at (forward) and 5′-TCACTGCATTCTAGTTGTGGT-3′ (reverse).
10
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Dox treatment. To suppress expression of the TDP-43M337V transgene in
NEF-tTA/TDP-43M337V and ChAT-tTA/TDP-43M337V rats in embryonic and
postnatal stages, Dox was constantly given to breeding rats in drinking water
(50 μg/ml) as described previously (3, 31). To restore TDP-43M337V expression, Dox was withdrawn from NEF-tTA/TDP-43M337V and ChAT-tTA/
TDP-43M337V rats at the age of 60 days. To stop TDP-43M337V from further
expression in diseased rats in a timely manner, Dox was subcutaneously
injected (4 mg/kg/d for 5 days) and was simultaneously given in drinking
water (500 μg/ml). Dox was maintained at 500 μg/ml in drinking water
until diseased rats were terminated.
Behavioral tests and disease stages. Grip strength of forepaws and hind paws
was measured with a grip-strength meter (Columbus Instruments). Mobility was monitored by an open-field activity assay (Med Associates), which
measured the total distance a rat traveled within 20 minutes. Grip strength
and mobility were used for determining disease onset and progression in
rats. Disease onset was defined as unrecoverable reduction of travel distance or grip strength. Paralysis was defined as occurrence of dragging legs
or as inability to retract legs individually. Disease end stages were defined
as inability to retract 2 or more legs, as inability to right itself when a rat
was placed on its side, or as a severe loss of body weight (>30%).
Cresyl violet staining and stereological cell counting. Coronal sections of rat forebrain or cross sections of rat spinal cord were stained with cresyl violet for
cell counting. Total neurons in the dentate gyrus of 1 hemisphere were estimated by unbiased stereological cell counting. Every 12th section (20 μm)
of the dentate gyrus was counted for neurons (a total of 17 to 22 sections
counted). To increase the accuracy of cell counting, a long segment of lumbar
cord (L3–L5) was assessed for motor neurons. The lumbar cord was cut into
consecutive sections (30 μm), and every tenth section was counted for motor
neurons on both sides of L3–L5 cords (a total of 15 to 20 sections counted).
Stereological cell counting was done as described previously (3, 31).
Toluidine blue staining and electromicroscopy. As described previously (3, 31),
the ultrastructure of axons in L3 ventral and dorsal roots was assessed
by electromicroscopy and by toluidine blue staining. Deeply anesthetized
rats were perfused with a mixture of 4% PFA and 2% glutaraldehyde. Nerve
roots were dissected and post-fixed in the same fixative at 4°C overnight.
Fixed tissues were embedded in Epon 812 and cut into semithin (1 μm)
and thin (80 nm) sections. Semithin sections stained with 1% toluidine
blue were examined under a light microscope, and thin sections stained
with uranyl acetate and lead citrate were examined under a transmission
electron microscope.
X-gal staining and silver staining. Deeply anesthetized rats were perfused
with 4% PFA for 2 hours. Lumbar cord was dissected and cut into cross
sections of 30 μm on a Cryostat. At room temperature, tissue sections
were stained for 24 hours in PBS solution composed of 1 mg/ml of
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl2, 0.02%
NP-40, and 0.01% sodium deoxycholate. Sections stained with X-gal were
counterstained with fast red. As described previously (3), degenerating
neurons in spinal cord were detected by Bielschowsky silver staining on
paraffin-embedded sections (10 μm).
Histology and histochemistry in skeletal muscles. As described previously (3, 31),
the structure of gastrocnemius muscle was assessed by H&E staining and
by histochemistry for nonspecific esterase and ATPase. Fresh muscle was
snap-frozen in isopentane/liquid nitrogen and was cut into cross sections
(10 μm) on a Cryostat. Nonspecific esterase activity was detected using
α-napthyl acetate protocol. Myosin ATPase staining (pH4.6) was employed
to show 3 types of skeletal muscle fibers. Regenerated muscle usually presents as accumulated fibers of the same type and of varied sizes.
Antibodies. The following primary antibodies were used in this study: chicken anti-ubiquitin (Sigma-Aldrich), goat anti-ChAT (Millipore), guinea pig

anti-GLT1 (Millipore), mouse monoclonal anti-APC (Calbiochem), mouse
monoclonal anti–β-gal (clone GAL-40; Sigma-Aldrich), mouse monoclonal
anti-GAPDH (Abcam), mouse monoclonal anti-human TDP-43 (Abnova,
clone 2E2-D3), rabbit anti-GFAP (DAKO North America), and rabbit anti–
Iba-1 (Wako Chemicals USA). Polyclonal antibody against NeuN was raised
in rabbits with a peptide (MAQPYPPAQYPPC) and was affinity purified.
Immunoblotting, immunohistochemistry, and immunofluorescence staining. As
described previously (3), the expression levels of human TDP-43 in transgenic tissues were estimated by immunoblotting. The same membrane was
incubated first with antibody to human TDP-43 and then with antibody
to GAPDH after stripping. Forebrain and spinal cord were cut into coronal or cross sections on a Cryostat, respectively. Immunohistochemistry
was done for human TDP-43, rat GFAP, rat Iba-1, rat ubiquitin, and rat
NG2. Immunostained sections were visualized using an ABC Kit in combination with diaminobenzidine (Vector). Some immunostained sections
were counterstained lightly with hematoxylin to display nuclei. Doublelabel immunofluorescence staining was used to show the colocalization of
human TDP-43 with rat GFAP, rat NeuN, rat APC, rat ChAT, rat ubiquitin,
or transgenic LacZ. Immunofluorescence staining and confocal microscopy were done as described previously (3, 31).
Quantitative PCR. Transgene copy and gene expression at the mRNA
level were determined by quantitative PCR. The copy number of the tTA
transgene was determined by quantitative PCR, as described in our publication (29). Expression of both human and rat TDP-43 mRNA was assessed
by quantitative PCR with 2 pairs of primers. The first pair of primers was
designed to amplify a fragment common to both human and rat TDP-43
mRNA: 5′-TGAGCCCATTGAAATACCATC-3′ (forward) and 5′-TACACTGAGACACTGGATTC-3′ (reverse). The second pair of primers was designed
to amply the rat L17 gene: 5′-TGGTTCGCTACTCCCTTGAC-3′ (forward)
and 5′-CTTGATGGCCTGGGCAGTT-3′ (reverse). TDP-43 mRNA levels
were first normalized to L17 mRNA, and the fold change of expression levels
in transgenic cells was calculated relative to that of nontransgenic cells.
Statistics. The numbers of hippocampal neurons and spinal motor neurons were compared between groups of rats with different genotypes, and
statistical differences in the numbers were analyzed by unpaired t test.
P < 0.05 was considered significant.
Study approval. Animal use was in accord with NIH guidelines, and the
animal use protocol was approved by the Institutional Animal Care and
Use Committees at Thomas Jefferson University.
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